Form4insider filings, from the source

SEC Form 4 · accession 0000911916-15-000189

CoLucid Pharmaceuticals, Inc. · CLCD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Arthur M Pappas
Director · 10% Owner
Period of report
May 11, 2015
Accepted (ET)
May 12, 2015 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2May 11, 2015C1,588,607—A1,588,609IBy A. M. Pappas Life Science Ventures III, L.P.
Common StockF1,F3May 11, 2015C98,757—A98,757IBy PV III CEO Fund, L.P.
Common StockF2May 11, 2015P282,440$10.00A1,871,049IBy A. M. Pappas Life Science Ventures III, L.P.
Common StockF3May 11, 2015P17,560$10.00A116,317IBy PV III CEO Fund, L.P.
Common StockF4holding———5,528IBy A.M. Pappas & Associates, LLC

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Convertible Preferred StockF2,F1,F5—May 11, 2015C578,297D——Common Stock578,2970I
Series A Convertible Preferred StockF3,F1,F5—May 11, 2015C35,953D——Common Stock35,9530I
Series B Convertible Preferred StockF2,F1,F5—May 11, 2015C675,588D——Common Stock675,5880I
Series B Convertible Preferred StockF3,F1,F5—May 11, 2015C41,996D——Common Stock41,9960I
Series C Convertible Preferred StockF2,F1,F5—May 11, 2015C334,722D——Common Stock334,7220I
Series C Convertible Preferred StockF3,F1,F5—May 11, 2015C20,808D——Common Stock20,8080I

Explanation of responses